Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA Rapport sur les actions

Capitalisation boursière : US$3.8m

Hepion Pharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Hepion Pharmaceuticals's earnings have been declining at an average annual rate of -24%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Informations clés

-24.0%

Taux de croissance des bénéfices

86.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie6.0%
Taux de croissance des recettesn/a
Rendement des fonds propres-796.4%
Marge netten/a
Dernière mise à jour des bénéfices30 Jun 2024

Mises à jour récentes des performances passées

Pas de mise à jour

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

Ventilation des recettes et des dépenses

Comment Hepion Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqCM:HEPA Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 240-28824
31 Mar 240-39928
31 Dec 230-491036
30 Sep 230-481038
30 Jun 230-461135
31 Mar 230-521139
31 Dec 220-451033
30 Sep 220-451033
30 Jun 220-461033
31 Mar 220-341021
31 Dec 210-331020
30 Sep 210-281016
30 Jun 210-251014
31 Mar 210-22913
31 Dec 200-20812
30 Sep 200-18710
30 Jun 200-1367
31 Mar 200-1555
31 Dec 190-1253
30 Sep 190-1253
30 Jun 190-2064
31 Mar 190-1776
31 Dec 180-1878
30 Sep 180-17710
30 Jun 180-14712
31 Mar 180-8713
31 Dec 170-13713
30 Sep 170-16714
30 Jun 170-15714
31 Mar 170-22714
31 Dec 160-18615
30 Sep 160-17614
30 Jun 160-17615
31 Mar 160-17615
31 Dec 150-21614
30 Sep 150-26612
30 Jun 150-2268
31 Mar 150-1245
31 Dec 140-1432
30 Sep 140-721

Des revenus de qualité: HEPA is currently unprofitable.

Augmentation de la marge bénéficiaire: HEPA is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: HEPA is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accélération de la croissance: Unable to compare HEPA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: HEPA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement des fonds propres

ROE élevé: HEPA has a negative Return on Equity (-796.38%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé